Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited.

PURPOSE Interstitial deletions of chromosome 5q are common in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), pointing toward the pathogenic role of this region in disease phenotype and clonal evolution. The higher level of resolution of single-nucleotide polymorphism array (SNP-A) karyotyping may be used to find cryptic abnormalities and to precisely define the topographic features of the genomic lesions, allowing for more accurate clinical correlations. PATIENTS AND METHODS We analyzed high-density SNP-A karyotyping at diagnosis for a cohort of 1,155 clinically well-annotated patients with malignant myeloid disorders. results: We identified chromosome 5q deletions in 142 (12%) of 1,155 patients and uniparental disomy segments (UPD) in four (0.35%) of 1,155 patients. Patients with deletions involving the centromeric and telomeric extremes of 5q have a more aggressive disease phenotype and additional chromosomal lesions. Lesions not involving the centromeric or telomeric extremes of 5q are not exclusive to 5q- syndrome but can be associated with other less aggressive forms of MDS. In addition, larger 5q deletions are associated with either del(17p) or UPD17p. In 31 of 33 patients with del(5q) AML, either a deletion involving the centromeric and/or telomeric regions or heterozygous mutations in NPM1 or MAML1 located in 5q35 were present. CONCLUSION Our results suggest that the extent of the affected region on 5q determines clinical characteristics that can be further modified by heterozygous mutations present in the telomeric extreme.

[1]  T. Suda,et al.  Faculty Opinions recommendation of A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. , 2011 .

[2]  C. Steidl,et al.  Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q , 2011, Leukemia.

[3]  A. Aventín,et al.  NPM1 Deletion Is Associated with Gross Chromosomal Rearrangements in Leukemia , 2010, PloS one.

[4]  A. Tefferi,et al.  WHO-defined ‘myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations , 2010, Leukemia.

[5]  A. Jankowska,et al.  Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome‐wide single nucleotide polymorphism array analysis , 2010, Genes, chromosomes & cancer.

[6]  M. McDevitt,et al.  TP53 Mutations in Myeloid Malignancies are either Homozygous or Hemizygous due to Copy Number-Neutral Loss of Heterozygosity or Deletion of 17p , 2009, Leukemia.

[7]  Wei Zhang,et al.  Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. , 2009, Cancer research.

[8]  P. Nguyen,et al.  Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.

[9]  J. Boultwood,et al.  Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays , 2008, Haematologica.

[10]  J. Clohessy,et al.  Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. , 2008, Blood.

[11]  C. O'keefe,et al.  Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. , 2008, Blood.

[12]  Goberdhan P Dimri,et al.  The Notch Regulator MAML1 Interacts with p53 and Functions as a Coactivator* , 2007, Journal of Biological Chemistry.

[13]  S. Nimer,et al.  Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Pandolfi,et al.  Role of nucleophosmin in embryonic development and tumorigenesis , 2005, Nature.

[15]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[16]  J. Boultwood,et al.  NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q). , 2004, Haematologica.

[17]  C. Schoch,et al.  Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 , 2004, Leukemia.

[18]  E. Masliah,et al.  β-Synuclein Displays an Antiapoptotic p53-dependent Phenotype and Protects Neurons from 6-Hydroxydopamine-induced Caspase 3 Activation , 2003, Journal of Biological Chemistry.

[19]  E. Masliah,et al.  Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson's disease. , 2003, The Journal of biological chemistry.

[20]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[21]  A. Kasprzyk,et al.  Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. , 2002, Blood.

[22]  N. Zhao,et al.  Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). , 2001, Genomics.

[23]  J Boultwood,et al.  Transcription mapping of the 5q- syndrome critical region: cloning of two novel genes and sequencing, expression, and mapping of a further six novel cDNAs. , 2000, Genomics.

[24]  L. Nagarajan,et al.  Deletions of chromosome 5q13.3 and 17p loci cooperate in myeloid neoplasms. , 2000, Blood.

[25]  Cervera,et al.  Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes , 2000, British journal of haematology.

[26]  M. Uesugi,et al.  The α-helical FXXΦΦ motif in p53: TAF interaction and discrimination by MDM2 , 1999 .

[27]  Weiya Ma,et al.  Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. , 1999, Cancer research.

[28]  M. Uesugi,et al.  The alpha-helical FXXPhiPhi motif in p53: TAF interaction and discrimination by MDM2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[30]  K. Kinzler,et al.  A model for p53-induced apoptosis , 1997, Nature.

[31]  V. Buckle,et al.  Molecular mapping of uncharacteristically small 5q deletions in two patients with the 5q- syndrome: delineation of the critical region on 5q and identification of a 5q- breakpoint. , 1994, Genomics.

[32]  R. Espinosa,et al.  Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Henderson,et al.  International Standing Committee on Human Cytogenetic Nomenclature , 1976 .